Understanding how lung cancer develops and interacts with the immune system
Spatial and temporal tumor-immune co-evolution and interactions that model lung adenocarcinoma development
['FUNDING_U01'] · UNIVERSITY OF TX MD ANDERSON CAN CTR · NIH-10880543
This study is looking at how lung adenocarcinoma, the most common type of lung cancer, starts by exploring how different cells in the lung, especially immune and lung cells, work together and change over time, which could help find ways to catch and treat lung cancer earlier.
Quick facts
| Phase | ['FUNDING_U01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF TX MD ANDERSON CAN CTR (nih funded) |
| Locations | 1 site (HOUSTON, UNITED STATES) |
| Trial ID | NIH-10880543 on ClinicalTrials.gov |
What this research studies
This research investigates the early events that lead to the development of lung adenocarcinoma, the most common type of lung cancer. By examining how different cell populations in the lung, particularly immune cells and epithelial cells, interact and evolve over time, the study aims to uncover the mechanisms that drive cancer formation. Using advanced techniques like multi-region single-cell sequencing, researchers will analyze cellular changes in both tumor and adjacent normal tissues to identify potential targets for early intervention. This approach could help in developing strategies for earlier diagnosis and treatment of lung cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at high risk for lung adenocarcinoma, including smokers and those with a family history of lung cancer.
Not a fit: Patients with advanced lung cancer or those who do not have lung adenocarcinoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved early detection and treatment strategies for lung adenocarcinoma, potentially saving lives.
How similar studies have performed: Previous research has shown promise in understanding tumor-immune interactions in other cancers, suggesting that this approach could yield valuable insights for lung adenocarcinoma as well.
Where this research is happening
HOUSTON, UNITED STATES
- UNIVERSITY OF TX MD ANDERSON CAN CTR — HOUSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: KADARA, HUMAM — UNIVERSITY OF TX MD ANDERSON CAN CTR
- Study coordinator: KADARA, HUMAM
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancers